Chugai’s Tecentriq gets green light in Japan for hard-to-treat Thymic Carcinoma

The drug had previously received orphan drug designation for this rare cancer on March 31, 2025

Bayer wins Japan nod for finerenone in broad heart failure population

Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients

Wellcome injects £2 million to turbocharge UK regulation of digital mental health tech

Healthium Medtech to invest Rs. 150 crore in new Sri City facility, create 400 jobs

Moraine appointed as distributor for OTSAW’s Hospital robots in Japan

Moraine will serve as OTSAW’s exclusive distributor in Japan, deploying the Camello+ autonomous mobile robot and TransCar autonomous guided vehicle to support hospital logistics

Novo Nordisk to cut 9,000 jobs globally

Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients

Centrient Pharmaceuticals joins UNGC

Reinforcing commitment to ethical and sustainable growth

Venus Remedies joins United Nations Global Compact

This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD

Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)

Bayer files for approval of finerenone in heart failure in Japan

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure